| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/09/2005 | US20050123541 Anti-TNF antibodies, compositions, methods and uses |
| 06/09/2005 | US20050123539 administering molecules that block endogenous costimulatory (B7) interactions with cytotoxic t lymphocytes(CTLA4) and/or CD28 antigens |
| 06/09/2005 | US20050123536 Treatment of immunological disorders using anti-dc30 antibodies |
| 06/09/2005 | US20050123534 Humanised antibodies |
| 06/09/2005 | US20050123531 Administering to the individual therapeutically effective amount of human acid alpha-glucosidase at regular interval for therapy of glycogen storage disease type II |
| 06/09/2005 | US20050123529 Systems and methods related to degradation of uremic toxins |
| 06/09/2005 | US20050123528 plant extracts used to break down polysaccharide cell walls and proteins fungi, mycelium and spores, by neutralization; applying by spraying, fumigation, dipping, or soaking and drenching |
| 06/09/2005 | US20050123524 Pharmaceutical compositions and methods for treating neuronal damages and neurodegenerative diseases |
| 06/09/2005 | US20050123516 Delivering a neurotrophic formulation comprising a neurotrophin encoding lentiviral expression vector, into one or more delivery sites within a region of the brain containing targeted neurons expressed for therapy of brain disorder |
| 06/09/2005 | US20050123512 Binding agents, vectors, host cells; gene therapy; nucleotide sequence with DNA insert encoding polypeptide; genetic engineering; medical diagnosis |
| 06/09/2005 | US20050123510 attenuated DNA viruses which increases production of chemokines |
| 06/09/2005 | US20050123509 Modulating charge density to produce improvements in the characteristics of spray-dried proteins |
| 06/09/2005 | US20050123508 human granulocyte colony stimulating factor polypeptides having amino acid replacements in the sequence, used for treating hematopoietic, neurological or reproductive disorders |
| 06/09/2005 | US20050123506 Administering a NF- kappa B inhibitor in conjunction with the administration of a chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased |
| 06/09/2005 | US20050123481 Radio-opaque polymeric biomaterials |
| 06/09/2005 | US20050122412 Digital camera |
| 06/09/2005 | DE4142157B4 Opioid-Peptide, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzung Opioid peptides, process for their preparation and pharmaceutical composition containing the |
| 06/09/2005 | DE10351471A1 Polyvalente Allergievakzine Polyvalent allergy vaccine |
| 06/09/2005 | DE102004016065B3 Bone substitute material comprises a porous material impregnated with a solution containing factor XIII |
| 06/09/2005 | CA2548202A1 Use of shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo |
| 06/09/2005 | CA2547326A1 Novel muscle growth regulator |
| 06/09/2005 | CA2547140A1 Glycopegylated erythropoietin |
| 06/09/2005 | CA2547126A1 Substance binding human igg fc receptor iib (fcyriib) |
| 06/09/2005 | CA2546863A1 Chaperone-based therapy for niemann-pick disease |
| 06/09/2005 | CA2546747A1 Ttbks as modifiers of the beta catenin pathway and methods of use |
| 06/09/2005 | CA2546703A1 Regulation of sperm function |
| 06/09/2005 | CA2546677A1 Pharmaceutical formulations for the sustained release of interferons and therapeutic applications thereof |
| 06/09/2005 | CA2546675A1 Pharmaceutical formulations for the sustained release of one or more active principles and applications thereof, such as therapeutic applications |
| 06/09/2005 | CA2546665A1 Protein from horn fly saliva that disrupts hemostasis |
| 06/09/2005 | CA2546654A1 Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer |
| 06/09/2005 | CA2546619A1 Il-23 and its receptor; related reagents and methods |
| 06/09/2005 | CA2546580A1 Homogeneous preparations of chimeric proteins |
| 06/09/2005 | CA2546498A1 Peptide increasing fusiogenic capacity of a gamete |
| 06/09/2005 | CA2546360A1 Methods of treating diseases and disorders by targeting multiple kinases |
| 06/09/2005 | CA2546290A1 Depeptidized inhibitors of hepatitis c virus ns3 protease |
| 06/09/2005 | CA2546287A1 Reduction of dermal scarring |
| 06/09/2005 | CA2546180A1 Plant extracts for the treatment of increased bone resorption |
| 06/09/2005 | CA2546042A1 Amelioration of macular degeneration and other ophthalmic diseases |
| 06/09/2005 | CA2545867A1 Anti-il-20 antibodies and binding partners and methods of using in inflammation |
| 06/09/2005 | CA2545815A1 Adenoviral vectored tnf-a and chemoradiation to treat cancer |
| 06/09/2005 | CA2545575A1 Pharmaceutical formulations for the sustained release of interleukins and therapeutic applications thereof |
| 06/09/2005 | CA2545473A1 Macromolecular drug complexes having improved stability and therapeutic use of the same |
| 06/09/2005 | CA2543566A1 B-cell-targeted toxin for immuno response reduction |
| 06/09/2005 | CA2542546A1 Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation |
| 06/09/2005 | CA2536242A1 Implantable sensors and implantable pumps and anti-scarring agents |
| 06/09/2005 | CA2536192A1 Soft tissue implants and anti-scarring agents |
| 06/09/2005 | CA2536188A1 Electrical devices and anti-scarring agents |
| 06/09/2005 | CA2518101A1 Compositions and methods for the treatment of systemic lupus erythematosis |
| 06/08/2005 | EP1538210A2 Dna-based vaccination of fish by immersion |
| 06/08/2005 | EP1538208A2 Mutants of streptococcal toxin A and methods of use |
| 06/08/2005 | EP1538202A2 Production of human alpha-galactosidase A |
| 06/08/2005 | EP1538199A1 Pituitary differentiation factor and methods of use thereof |
| 06/08/2005 | EP1538196A1 Fibrin-containing composition |
| 06/08/2005 | EP1538163A2 Phosphorylated Amyloid-Beta 1-43 Protein and its use in the treatment of Alzheimer's disease |
| 06/08/2005 | EP1538162A2 Compositions for altering mucus secretion |
| 06/08/2005 | EP1538160A1 Substituted Isoquinolin-3-carboxyamides, their preparation and medical use |
| 06/08/2005 | EP1538158A1 Proline ester and preparation containing the same for percutaneous administration |
| 06/08/2005 | EP1538157A2 Isolation and use of SH3 binding peptides |
| 06/08/2005 | EP1537896A1 Compound mixtures based on sulphur containing amino acids, antioxidants, phospholipids and vitamins for the preparation of a medicament for treating L-diabetes and/or associated diseases. |
| 06/08/2005 | EP1537882A1 Reverse phase connective tissue repair composition |
| 06/08/2005 | EP1537878A1 Immunopotentiating compositions |
| 06/08/2005 | EP1537877A2 Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| 06/08/2005 | EP1537876A1 Erythropoietin solution formulation |
| 06/08/2005 | EP1537875A1 Preventive/remedy for arteriosclerosis |
| 06/08/2005 | EP1537870A2 Methods and compositions for treating cancer |
| 06/08/2005 | EP1537865A1 Use of sulfur containing compounds and proteolytic enzymes for the prevention and therapy of the UDP-Glucuronosyltransferase 1 deficient Type II Diabetes mellitus |
| 06/08/2005 | EP1537864A1 Use of amino acids and sulphur-containing compounds for the prevention and therapy of the UDP Glucuronosyltransferase 1 deficient Type II Diabetes mellitus |
| 06/08/2005 | EP1537862A1 Novel use of peptide compounds for treating central neuropathic pain |
| 06/08/2005 | EP1537860A1 Vaccine composition, method of preparing the composition and method of vaccinating vertebrates |
| 06/08/2005 | EP1537858A1 Drug delivery vehicles and uses thereof |
| 06/08/2005 | EP1537417A2 Method of diagnosing colon and gastric cancers |
| 06/08/2005 | EP1537243A1 Method of diagnosing ovarian endometriosis |
| 06/08/2005 | EP1537237A2 Use of pp2a phosphatase modulators in the treatment of mental disorders |
| 06/08/2005 | EP1537212A2 Human lipid phosphate phosphatases and uses thereof for treating neuronal diseases |
| 06/08/2005 | EP1537211A2 Isolated cytokine receptor licr-2 |
| 06/08/2005 | EP1537210A1 Decoy-oligonucleotide-inhbition of cd40-expression |
| 06/08/2005 | EP1537209A2 Functional correction of the sp -786 /sp c/t variance of the human i enos /i gene |
| 06/08/2005 | EP1537208A1 Non-sequence complementary antiviral oligonucleotides |
| 06/08/2005 | EP1537207A2 Recombinant colstridium neurotoxin fragments |
| 06/08/2005 | EP1537204A2 Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells |
| 06/08/2005 | EP1537203A1 USE OF DENDRITIC CELLS (DCs) EXPRESSING INTERLEUKIN 12 (IL-12) |
| 06/08/2005 | EP1537195A1 Desinfecting composition |
| 06/08/2005 | EP1537145A1 Pharmaceutical compositions and medical treatments comprising notch ligand proteins |
| 06/08/2005 | EP1537142A1 Akap18 delta, a novel splicing variant of a protein kinase a anchor protein and the use of the same |
| 06/08/2005 | EP1537141A1 Parathyroid hormone-like polypeptides |
| 06/08/2005 | EP1537139A2 A mechanism for hiv-1 entry into host cells and peptides inhibiting this mechanism |
| 06/08/2005 | EP1537138A2 Receptors and membrane-associated proteins |
| 06/08/2005 | EP1537137A2 Stabilized bioactive peptides and methods of identification, synthesis, and use |
| 06/08/2005 | EP1536863A1 Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event |
| 06/08/2005 | EP1536839A2 Method for treating diseases with omega interferon |
| 06/08/2005 | EP1536837A1 Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors |
| 06/08/2005 | EP1536835A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| 06/08/2005 | EP1536834A2 Design of chemokine analogs for the treatment of human diseases |
| 06/08/2005 | EP1536829A2 Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin useful for the treatment of cancer and infectious disease |
| 06/08/2005 | EP1536828A2 Methods of delivery of exogenous proteins to the cytosol and uses thereof |
| 06/08/2005 | EP1536827A1 Use of protein kinase n beta |
| 06/08/2005 | EP1536826A2 Thymus-based tolerogenic approaches for type i diabetes. |
| 06/08/2005 | EP1536825A1 Interferon and immunoglobulin fc fragment hybrid |
| 06/08/2005 | EP1536824A2 Ubiquitin and ubiquitin related molecules for treatment and prevention of harmful activation of the immune system |
| 06/08/2005 | EP1536823A1 Use of erythopoietin |